Nivolumab for malignant peritoneal mesothelioma

BMJ Case Rep. 2020 Nov 30;13(11):e237721. doi: 10.1136/bcr-2020-237721.

Abstract

Malignant peritoneal mesothelioma (MPeM) is a highly malignant neoplasm of the peritoneum, which carries a poor prognosis. A 70-year-old man, who was employed in the shipbuilding industry and exposed to asbestos for 50 years, was found to have a low-density lesion in the peritoneum around the liver and spleen, associated with multiple mediastinal and parasternal lymphadenopathy. Laparoscopic exploration was performed, and biopsy specimen analysis led to a diagnosis of MPeM. Initial systemic chemotherapy comprising cisplatin and pemetrexed yielded a modest cytoreductive effect. However, 4 months later, the patient presented with abdominal distension and anorexia. CT images revealed massive ascites, bowel obstruction and an enlarged intra-abdominal tumour, which was considered progression of the MPeM. The patient was treated with nivolumab. Bowel obstruction was improved after the first administration, and his sense of abdomen distension completely disappeared after the third administration. This case supports the utility of immunotherapy in MPeM.

Keywords: cancer; chemotherapy; exposures.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Male
  • Mesothelioma, Malignant / diagnostic imaging
  • Mesothelioma, Malignant / drug therapy*
  • Nivolumab / therapeutic use*
  • Peritoneal Neoplasms / diagnostic imaging
  • Peritoneal Neoplasms / drug therapy*
  • Radiography, Abdominal
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents, Immunological
  • Immune Checkpoint Inhibitors
  • Nivolumab